Nature Communications (Jun 2022)
Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation
- Suyash Deodhar,
- Brady Sillman,
- Aditya N. Bade,
- Sean N. Avedissian,
- Anthony T. Podany,
- JoEllyn M. McMillan,
- Nagsen Gautam,
- Brandon Hanson,
- Bhagya L. Dyavar Shetty,
- Adam Szlachetka,
- Morgan Johnston,
- Michellie Thurman,
- Daniel J. Munt,
- Alekha K. Dash,
- Milica Markovic,
- Arik Dahan,
- Yazen Alnouti,
- Alborz Yazdi,
- Bhavesh D. Kevadiya,
- Siddappa N. Byrareddy,
- Samuel M. Cohen,
- Benson Edagwa,
- Howard E. Gendelman
Affiliations
- Suyash Deodhar
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Brady Sillman
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Aditya N. Bade
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Sean N. Avedissian
- Department of Pharmacy Practice and Science, University of Nebraska Medical Center
- Anthony T. Podany
- Department of Pharmacy Practice and Science, University of Nebraska Medical Center
- JoEllyn M. McMillan
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Nagsen Gautam
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center
- Brandon Hanson
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Bhagya L. Dyavar Shetty
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Adam Szlachetka
- Nebraska Nanomedicine Production Plant, University of Nebraska Medical Center
- Morgan Johnston
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Michellie Thurman
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Daniel J. Munt
- Department of Pharmacy Sciences, Creighton University
- Alekha K. Dash
- Department of Pharmacy Sciences, Creighton University
- Milica Markovic
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Arik Dahan
- Department of Clinical Pharmacology, Ben-Gurion University of the Negev
- Yazen Alnouti
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center
- Alborz Yazdi
- Exavir Therapeutics, Inc.
- Bhavesh D. Kevadiya
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Siddappa N. Byrareddy
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Samuel M. Cohen
- Department of Pathology and Microbiology, University of Nebraska Medical Center
- Benson Edagwa
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- Howard E. Gendelman
- Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center
- DOI
- https://doi.org/10.1038/s41467-022-30902-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
Here, using animal models, Deodhar et al. single parenteral dose of dolutegravir (DTG) prodrug nanocrystals sustains drug protein-adjusted 90% inhibitory concentration for up to a year, without injection site reactions or systemic toxicities.
